Evidence map›Paper›PMID 26276154›Full record

ArticleMolecular imaging and biology2016

The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.

Valerie S Honndorf, Holger Schmidt, Stefan Wiehr, Hans F Wehrl, Leticia Quintanilla-Martinez, Anke Stahlschmidt, Hervé Barjat, Sally-Ann Emmas, Bernd J Pichler

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Voxel-Based Analysis of the Relation of 3'-Deoxy-3'-[Molecular imaging and biology · 2022
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Valerie S HonndorfDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Tübingen, Germany.
Holger SchmidtDepartment of Radiology, Diagnostic and Interventional Radiology, Eberhard Karls University, Tübingen, Germany.
Stefan WiehrDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Tübingen, Germany.
Hans F WehrlDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Tübingen, Germany.
Leticia Quintanilla-MartinezInstitute for Pathology, Eberhard Karls University, Tübingen, Germany.
Anke StahlschmidtDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Tübingen, Germany.
Hervé BarjatPersonalized Healthcare and Biomarkers, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.
Sally-Ann EmmasPersonalized Healthcare and Biomarkers, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.
Bernd J PichlerDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Tübingen, Germany. Bernd.Pichler@med.uni-tuebingen.de.
University of Tübingen · DEAstraZeneca (United Kingdom) · GBSiemens (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePositron emission tomography (PET) and diffusion-weighted MRI (DW-MRI) were used to characterize the treatment effects of the MEK1/2 inhibitor selumetinib (AZD6244), docetaxel, and their combination in HCT116 tumor-bearing mice on the molecular level. PROCEDURES: Mice were treated with vehicle, selumetinib (25 mg/kg), docetaxel (15 mg/kg), or a combination of both drugs for 7 days and imaged at four time points with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) or 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) followed by DW-MRI to calculate the apparent diffusion coefficient (ADC). Data was cross-validated using the Pearson correlation coefficient (PCC) and compared to histology (IHC).

resultsEach drug led to tumor growth inhibition but their combination resulted in regression. Separate analysis of PET or ADC could not provide significant differences between groups. Only PCC combined with IHC analysis revealed the highest therapeutic impact for combination therapy.

conclusionCombination treatment of selumetinib/docetaxel was superior to the respective mono-therapies shown by PCC of PET and ADC in conjunction with histology.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCell ProliferationColorectal NeoplasmsDideoxynucleosidesDiffusion Magnetic Resonance ImagingDocetaxelDrug SynergismFluorodeoxyglucose F18HCT116 CellsHumansImmunohistochemistryMicePositron-Emission TomographyTaxoidsalovudineAZD 6244BenzimidazolesDideoxynucleosidesDocetaxelFluorodeoxyglucose F18TaxoidsApparent diffusion coefficientDiffusion-weighted magnetic resonance imagingDocetaxelHCT 116 tumor xenograft mouse modelPearson correlation coefficientPositron emission tomographySelumetinibTreatment effect

Identifiers

PMID26276154
OpenAlexW1120064563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.